Clinical Research Directory

Inclusion Criteria: 1. Written informed consent 2. Age between 18 and 85 years 3. Scheduled to undergo elective unilateral primary THA and eligible for perioperative management based on the ERAS protocol 4. Baseline Timed Up and Go (TUG) test scoring \< 20 seconds, corresponding to a good mobility status before surgery 5. Capability to understand and comply with the protocol requirements (e.g., sufficient knowledge of German language to answer the questionnaires, ability to swallow intact capsules). 6. Pregnancy and contraception: 1. Pregnancy test: Negative serum pregnancy test at screening for women of childbearing potential (WOCBP). 2. Contraception: WOCBP and men who are able to father a child, willing to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at informed consent, for the duration of drug treatment and allowing for a safe wash out period of at least 5 days for female or for male subjects after the last dose of trial medication. This is a very conservative estimate, considering the 'worst case scenario' of a substantially prolonged half-life up to 13 hours (e.g., in older patients and/or those with renal dysfunction) (28), and calculating for at least 8 half-lives to ensure practically non-detectable levels and effects of rivaroxaban. Exclusion Criteria: 1. Previous DVT or PE 2. Hip or lower limb fracture in the previous three months 3. Major surgical procedure within the previous three months 4. Active cancer defined as metastatic cancer, or cancer requiring chemotherapy or radiation therapy 5. Active peptic ulcer disease, gastritis, or prior gastrointestinal bleeding 6. Obesity with body mass index (BMI) \> 40 kg/m2 body surface area 7. Severe renal impairment defined as estimated glomerular filtration rate \< 30ml/min 8. Severe hepatic impairment defined as Child Pugh Class B or C 9. Uncontrolled intercurrent illness (i.e., active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, interstitial lung disease, serious gastrointestinal conditions \[e.g., diarrhea, malabsorption\], psychiatric illness) 10. Active or recent major bleeding at any site, or presence of any major risk factor for bleeding, which, in the judgment of the investigator, may significantly increase the bleeding risk during postoperative anticoagulation treatment 11. Any other medical condition representing a contraindication to discharge within 6 days after surgery 12. Expected requirement for major surgery within a 90-day period post THA 13. Need for long-term anticoagulation (e.g., atrial fibrillation, previous VTE) 14. Need for chronic antiplatelet therapy except for acetylsalicylic acid (ASA) at a dose ≤ 100 mg daily or clopidogrel 75 mg daily 15. Previous participation in this trial 16. Life expectancy \< 6 months 17. Participation in another interventional clinical trial within the last 30 days prior to inclusion, unless during the observational follow-up period 18. History of hypersensitivity to the investigational medicinal product (IMP) or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the IMP